Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Applied Therapeutics, Inc.

Group 1 - A class action has been filed against Applied Therapeutics, Inc. for allegedly misleading investors regarding its lead drug candidate, govorestat, during the period from January 3, 2024, to December 2, 2024 [1][2][7] - The complaint highlights that Applied Therapeutics received a Complete Response Letter (CRL) from the FDA on November 27, 2024, due to deficiencies in the clinical application, leading to a significant decline in stock price from $8.57 to $1.75, representing a total decline of over 80% [2][8] - The company is accused of making misleading statements about the efficacy of govorestat in treating Galactosemia, including positive outcomes from various clinical trials and confidence in its New Drug Application (NDA) [7] Group 2 - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by February 18, 2025, and can remain absent class members if they choose not to participate [3] - Robbins LLP, the law firm handling the case, has a history of assisting shareholders in recovering losses and improving corporate governance since 2002 [4]